Mahmoud Zureik, Phamacoepidemiology professor

Phamacoepidemiology professor
EPI-PHARE, French National Agency for Medicines and Health Products Safety (ANSM) and French National Health Insurance (CNAM), 143-147 Boulevard Anatole France, 93285, Saint-Denis, France, France

Phamacoepidemiology professor

Poster(s):

• (009) Drug survival and safety of biosimilars compared with originator adalimumab for Psoriasis: a multinational cohort study
  Monday, August 26, 2024

  8:00 AM – 6:00 PM CEST

• (221) Levonorgestrel-releasing Intrauterine Systems And Copper Intrauterine Devices Utilization In France: Changes From The Last Decade
  Monday, August 26, 2024

  8:00 AM – 6:00 PM CEST

• (226) Use of progestogens and the risk of intracranial meningioma: a national case-control study
  Monday, August 26, 2024

  8:00 AM – 6:00 PM CEST

• (238) Influence of relative age on initiation of methylphenidate and speech therapy in children aged 5 to 10 years: a French nationwide cohort study
  Wednesday, August 28, 2024

  8:00 AM – 1:30 PM CEST

• (253) COVID-19 vaccination rate among pregnant women in France: a nationwide study
  Tuesday, August 27, 2024

  8:00 AM – 6:00 PM CEST

• (339) Eighteen-month follow-up cohort study of post-vaccination COVID-19 myocarditis in France compared with other forms of myocarditis
  Tuesday, August 27, 2024

  8:00 AM – 6:00 PM CEST

• (CSPOT40) Use and Outcomes of Trastuzumab Deruxtecan in HER2-positive and HER2-low Metastatic Breast Cancer in Real-World Setting: A Nationwide Cohort Study
  Wednesday, August 28, 2024

  8:00 AM – 1:30 PM CEST